Bifogade filer
Kurs & Likviditet
Kalender
2024-10-31 | Kvartalsrapport 2024-Q3 |
2024-08-16 | Kvartalsrapport 2024-Q2 |
2024-06-05 | Ordinarie utdelning NAVA 0.00 NOK |
2024-06-04 | Årsstämma 2024 |
2024-04-30 | Kvartalsrapport 2024-Q1 |
2024-02-15 | Bokslutskommuniké 2023 |
2023-11-01 | Kvartalsrapport 2023-Q3 |
2023-08-11 | Kvartalsrapport 2023-Q2 |
2023-06-02 | Ordinarie utdelning NAVA 0.00 NOK |
2023-06-01 | Årsstämma 2023 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-02-16 | Bokslutskommuniké 2022 |
2022-11-01 | Kvartalsrapport 2022-Q3 |
2022-08-12 | Kvartalsrapport 2022-Q2 |
2022-06-03 | Ordinarie utdelning NAVA 0.00 NOK |
2022-06-02 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-02-17 | Bokslutskommuniké 2021 |
2021-11-04 | Kvartalsrapport 2021-Q3 |
2021-08-13 | Kvartalsrapport 2021-Q2 |
2021-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2021-06-03 | Årsstämma 2021 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-02-18 | Bokslutskommuniké 2020 |
2020-11-06 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2020-06-03 | Årsstämma 2020 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-03-11 | Extra Bolagsstämma 2020 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-11-01 | Kvartalsrapport 2019-Q3 |
2019-08-23 | Kvartalsrapport 2019-Q2 |
2019-05-29 | Ordinarie utdelning NAVA 0.00 NOK |
2019-05-28 | Årsstämma 2019 |
2019-05-15 | Kvartalsrapport 2019-Q1 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-12-20 | Extra Bolagsstämma 2018 |
2018-11-09 | Kvartalsrapport 2018-Q3 |
2018-08-24 | Kvartalsrapport 2018-Q2 |
2018-06-08 | Ordinarie utdelning NAVA 0.00 NOK |
2018-06-07 | Årsstämma 2018 |
2018-05-30 | Kvartalsrapport 2018-Q1 |
2018-02-15 | Bokslutskommuniké 2017 |
2017-11-10 | Kvartalsrapport 2017-Q3 |
2017-07-28 | Kvartalsrapport 2017-Q2 |
2017-06-07 | Ordinarie utdelning NAVA 0.00 NOK |
2017-06-06 | Årsstämma 2017 |
2017-05-10 | Kvartalsrapport 2017-Q1 |
2017-02-15 | Bokslutskommuniké 2016 |
2017-01-13 | Extra Bolagsstämma 2017 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-06-21 | Ordinarie utdelning NAVA 0.00 NOK |
2016-06-20 | Årsstämma 2016 |
2016-05-11 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-10-30 | Extra Bolagsstämma 2015 |
2015-10-30 | Kvartalsrapport 2015-Q3 |
2015-08-21 | Kvartalsrapport 2015-Q2 |
2015-06-09 | Ordinarie utdelning NAVA 0.00 NOK |
2015-06-08 | Årsstämma 2015 |
2015-04-28 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-10-31 | Kvartalsrapport 2014-Q3 |
2014-08-22 | Kvartalsrapport 2014-Q2 |
2014-06-10 | Årsstämma 2014 |
2014-05-06 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-30 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-23 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-15 | Bokslutskommuniké 2012 |
2012-02-10 | Bokslutskommuniké 2011 |
2011-10-21 | Kvartalsrapport 2011-Q3 |
2011-08-25 | Kvartalsrapport 2011-Q2 |
2011-05-05 | Kvartalsrapport 2011-Q1 |
2011-04-14 | Årsstämma 2011 |
2011-02-04 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-26 | Kvartalsrapport 2010-Q2 |
2010-05-05 | Kvartalsrapport 2010-Q1 |
2010-03-25 | Årsstämma 2010 |
2010-02-11 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.
Eroxon® was launched in Norway in February 2024 and has been very well received by Norwegian consumers. After only two weeks in the market, it was the bestseller at an online pharmacy. Strong sales resulted in Eroxon® ranking third on Navamedic's most sold products in the Consumer Health segment in the first quarter of 2024.
"Eroxon® is a fast, safe and easily available product developed to help men improve not only their sexual health but also their quality of life. We hope for a similar response in Sweden as in the UK and Norway. Over time, we see greater growth potential in Sweden because Eroxon® will be the only non-prescription treatment for erectile dysfunction in the market," says Jack Spira, Medical Director at Navamedic.
Four out of ten men in Sweden have experienced erectile dysfunction at some point, according to a new survey conducted on behalf of Navamedic. Medication is the most common measure, but the vast majority do not seek any help at all[1].
Eroxon® offers a range of features which distinguishes it from other treatments of erectile dysfunction. First and foremost, it is an effective and fast-acting gel which typically helps men get an erection within ten minutes. It has a very good safety profile due to local effect with no systemic absorption. Eroxon® is approved as a treatment for erectile dysfunction in the EU and the US.
[1] Survey conducted in Sweden by Novus 28 March - 11 April 2024.
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com